INNOVATION IS IN OUR BLOOD
Imagine being able to treat yourself using your own blood.
At ErythroSIGHT (a spinout being incubated at ANU and Clear Vision Research), we are committed to developing next-generation therapeutics for the treatment of retinal- and neuro-degenerations. Using Red Blood Cell Derived Extracellular Vesicles (RBC-EVs), we are developing a safe, inexpensive and personalized blood-derived product to treat Age-related Macular Degeneration (AMD), the most common form of uncurable blindness in the western world.
Meet The Team
For more information on ErythroSIGHT please contact one of our team members.